BCYC

SEC source: 0001415889-24-024772 · form4-10042024_041013.xml · nonDerivative · entry 1

Lee Kevin · CIK 0001776938 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 380,864

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-024770 · form4-10042024_041009.xml · nonDerivative · entry 1

Skynner Michael · CIK 0001776582 · CHIEF TECHNOLOGY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,945

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-024769 · form4-10042024_041006.xml · nonDerivative · entry 1

Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,302

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-024768 · form4-10042024_041004.xml · nonDerivative · entry 1

Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,822

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-024767 · form4-10042024_041001.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,922

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-019389 · form4-07082024_100702.xml · nonDerivative · entry 1

Hannay Michael Charles Ferguson · CIK 0002015378 · CHIEF PROD & SUPPLY CHAIN OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,645

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-019385 · form4-07082024_060705.xml · nonDerivative · entry 1

Keen Nicholas · CIK 0001776881 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,024

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-019384 · form4-07082024_060703.xml · nonDerivative · entry 1

Lee Kevin · CIK 0001776938 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 384,076

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-019388 · form4-07082024_100725.xml · nonDerivative · entry 1

Skynner Michael · CIK 0001776582 · CHIEF TECHNOLOGY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,917

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-019387 · form4-07082024_060709.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,075

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-019386 · form4-07082024_060707.xml · nonDerivative · entry 1

Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,794

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-019383 · form4-07082024_060701.xml · nonDerivative · entry 1

Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,274

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.63 to $19.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-075569 · ownership.xml · derivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 17,840,603

Underlying: Ordinary Shares · 2,186,686 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · derivative.exercise_price: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F3 · derivative.exercise_price: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the Pre-Offering Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares became effective on June 16, 2024.

F1 · shares: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · shares: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F3 · shares: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the Pre-Offering Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares became effective on June 16, 2024.

F1 · price: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F1 · derivative.exercise_date: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · derivative.exercise_date: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F3 · derivative.exercise_date: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the Pre-Offering Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares became effective on June 16, 2024.

F12 · derivative.exercise_date: The Adviser on behalf of the Funds submitted written notice to the Issuer on May 28, 2024 of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on May 29, 2024 related to the May 2024 Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.

F1 · derivative.expiration_date: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · derivative.expiration_date: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F5 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F11 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I and the securities reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-075569 · ownership.xml · derivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,597,341

Underlying: Ordinary Shares · 196,098 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · derivative.exercise_price: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F3 · derivative.exercise_price: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the Pre-Offering Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares became effective on June 16, 2024.

F1 · shares: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · shares: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F3 · shares: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the Pre-Offering Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares became effective on June 16, 2024.

F1 · price: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F1 · derivative.exercise_date: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · derivative.exercise_date: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F3 · derivative.exercise_date: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the Pre-Offering Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares became effective on June 16, 2024.

F12 · derivative.exercise_date: The Adviser on behalf of the Funds submitted written notice to the Issuer on May 28, 2024 of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on May 29, 2024 related to the May 2024 Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.

F1 · derivative.expiration_date: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · derivative.expiration_date: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I and securities reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0000950170-24-075569 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,636,006

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · shares: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F3 · shares: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the Pre-Offering Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares became effective on June 16, 2024.

F1 · price: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F5 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F7 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share.

F8 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F9 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs.

F10 · ownership.nature: Pursuant to the policies of the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs.

F11 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I and the securities reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-075569 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 787,954

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F2 · shares: The Pre-Offering Non-Voting Ordinary Shares and the non-voting ordinary shares purchased in the Issuer's offering on May 29, 2024 ("May 2024 Non-Voting Ordinary Shares", and together with the Pre-Offering Non-Voting Ordinary Shares, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Ordinary Shares to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares, subject to adjustments detailed below (the "Beneficial Ownership Limitation") following such conversion.

F3 · shares: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the Pre-Offering Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares became effective on June 16, 2024.

F1 · price: On June 17, 2024, 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") converted, respectively, 196,098 and 2,186,686 non-voting ordinary shares of Bicycle Therapeutics plc (the "Issuer') acquired prior to the May 29, 2024 offering of the Issuer ("Pre-Offering Non-Voting Ordinary Shares") on a 1-for-1 basis without consideration into ordinary shares ("Ordinary Shares") of the Issuer issued in the form of American Depositary Shares ("ADS").

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I and securities reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F7 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share.

F8 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F9 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs.

F10 · ownership.nature: Pursuant to the policies of the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs.

SEC source: 0000950170-24-065961 · ownership.xml · derivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 20,027,289

Underlying: Ordinary Shares · 15,684,860 shares

Expires not disclosed

F1 · derivative.exercise_price: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") purchased, respectively, 1,429,986 and 15,684,860 non-voting ordinary shares ("May 2024 Non-Voting Ordinary Shares") of Bicycle Therapeutics plc (the "Issuer") for $21.42 per share pursuant to a private placement that closed on May 29, 2024 (the "Offering"). The May 2024 Non-Voting Ordinary Shares and the Pre-Offering Non-Voting Ordinary Shares (as defined below) (collectively, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into ordinary shares of the Issuer ("Ordinary Shares") to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, (continued in footnote 2)

F2 · derivative.exercise_price: would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares (the "Beneficial Ownership Limitation") following such conversion.By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the 4,705,882 Non-Voting Ordinary Shares held prior to the Offering ("Pre-Offering Non-Voting Ordinary Shares"). This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares will take effect on June 16, 2024.

F3 · derivative.exercise_price: The Adviser on behalf of the Funds submitted written notice to the Issuer on May 28, 2024 of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on May 29, 2024 related to the May 2024 Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.

F1 · derivative.exercise_date: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") purchased, respectively, 1,429,986 and 15,684,860 non-voting ordinary shares ("May 2024 Non-Voting Ordinary Shares") of Bicycle Therapeutics plc (the "Issuer") for $21.42 per share pursuant to a private placement that closed on May 29, 2024 (the "Offering"). The May 2024 Non-Voting Ordinary Shares and the Pre-Offering Non-Voting Ordinary Shares (as defined below) (collectively, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into ordinary shares of the Issuer ("Ordinary Shares") to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, (continued in footnote 2)

F2 · derivative.exercise_date: would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares (the "Beneficial Ownership Limitation") following such conversion.By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the 4,705,882 Non-Voting Ordinary Shares held prior to the Offering ("Pre-Offering Non-Voting Ordinary Shares"). This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares will take effect on June 16, 2024.

F3 · derivative.exercise_date: The Adviser on behalf of the Funds submitted written notice to the Issuer on May 28, 2024 of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on May 29, 2024 related to the May 2024 Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.

F1 · derivative.expiration_date: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") purchased, respectively, 1,429,986 and 15,684,860 non-voting ordinary shares ("May 2024 Non-Voting Ordinary Shares") of Bicycle Therapeutics plc (the "Issuer") for $21.42 per share pursuant to a private placement that closed on May 29, 2024 (the "Offering"). The May 2024 Non-Voting Ordinary Shares and the Pre-Offering Non-Voting Ordinary Shares (as defined below) (collectively, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into ordinary shares of the Issuer ("Ordinary Shares") to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, (continued in footnote 2)

F2 · derivative.expiration_date: would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares (the "Beneficial Ownership Limitation") following such conversion.By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the 4,705,882 Non-Voting Ordinary Shares held prior to the Offering ("Pre-Offering Non-Voting Ordinary Shares"). This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares will take effect on June 16, 2024.

F3 · derivative.expiration_date: The Adviser on behalf of the Funds submitted written notice to the Issuer on May 28, 2024 of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on May 29, 2024 related to the May 2024 Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.

F5 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit for Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F7 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-065961 · ownership.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,793,439

Underlying: Ordinary Shares · 1,429,986 shares

Expires not disclosed

F1 · derivative.exercise_price: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") purchased, respectively, 1,429,986 and 15,684,860 non-voting ordinary shares ("May 2024 Non-Voting Ordinary Shares") of Bicycle Therapeutics plc (the "Issuer") for $21.42 per share pursuant to a private placement that closed on May 29, 2024 (the "Offering"). The May 2024 Non-Voting Ordinary Shares and the Pre-Offering Non-Voting Ordinary Shares (as defined below) (collectively, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into ordinary shares of the Issuer ("Ordinary Shares") to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, (continued in footnote 2)

F2 · derivative.exercise_price: would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares (the "Beneficial Ownership Limitation") following such conversion.By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the 4,705,882 Non-Voting Ordinary Shares held prior to the Offering ("Pre-Offering Non-Voting Ordinary Shares"). This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares will take effect on June 16, 2024.

F3 · derivative.exercise_price: The Adviser on behalf of the Funds submitted written notice to the Issuer on May 28, 2024 of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on May 29, 2024 related to the May 2024 Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.

F1 · derivative.exercise_date: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") purchased, respectively, 1,429,986 and 15,684,860 non-voting ordinary shares ("May 2024 Non-Voting Ordinary Shares") of Bicycle Therapeutics plc (the "Issuer") for $21.42 per share pursuant to a private placement that closed on May 29, 2024 (the "Offering"). The May 2024 Non-Voting Ordinary Shares and the Pre-Offering Non-Voting Ordinary Shares (as defined below) (collectively, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into ordinary shares of the Issuer ("Ordinary Shares") to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, (continued in footnote 2)

F2 · derivative.exercise_date: would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares (the "Beneficial Ownership Limitation") following such conversion.By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the 4,705,882 Non-Voting Ordinary Shares held prior to the Offering ("Pre-Offering Non-Voting Ordinary Shares"). This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares will take effect on June 16, 2024.

F3 · derivative.exercise_date: The Adviser on behalf of the Funds submitted written notice to the Issuer on May 28, 2024 of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on May 29, 2024 related to the May 2024 Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.

F1 · derivative.expiration_date: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and, together with 667, the "Funds") purchased, respectively, 1,429,986 and 15,684,860 non-voting ordinary shares ("May 2024 Non-Voting Ordinary Shares") of Bicycle Therapeutics plc (the "Issuer") for $21.42 per share pursuant to a private placement that closed on May 29, 2024 (the "Offering"). The May 2024 Non-Voting Ordinary Shares and the Pre-Offering Non-Voting Ordinary Shares (as defined below) (collectively, the "Non-Voting Ordinary Shares") have no expiration date and are convertible immediately at any time at the option of the holder on a 1-for-1 basis without consideration into ordinary shares of the Issuer ("Ordinary Shares") to the extent that immediately prior to or after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, (continued in footnote 2)

F2 · derivative.expiration_date: would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares (the "Beneficial Ownership Limitation") following such conversion.By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. Baker Bros. Advisors LP (the "Adviser") on behalf of the Funds submitted written notice to the Issuer of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on April 16, 2024 related to the 4,705,882 Non-Voting Ordinary Shares held prior to the Offering ("Pre-Offering Non-Voting Ordinary Shares"). This increase in the Beneficial Ownership Limitation on the Pre-Offering Non-Voting Ordinary Shares will take effect on June 16, 2024.

F3 · derivative.expiration_date: The Adviser on behalf of the Funds submitted written notice to the Issuer on May 28, 2024 of an increase in the Beneficial Ownership Limitation from 9.99% to 19.9% on May 29, 2024 related to the May 2024 Non-Voting Ordinary Shares. This increase in the Beneficial Ownership Limitation on the May 2024 Non-Voting Ordinary shares will take effect on July 29, 2024.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit for Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0000950170-24-046415 · ownership.xml · derivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 24,000

Underlying: American Depositary Shares · 24,000 shares

Expires 2034-04-18

F10 · shares: Includes 24,000 Share Options granted by the Issuer to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the 2020 Plan. The Share Options have a strike price of $21.82 and vest in three equal annual installments beginning on April 18, 2025, provided, however, that all vesting of Share Options granted to a director shall cease if that director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

F10 · derivative.exercise_date: Includes 24,000 Share Options granted by the Issuer to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the 2020 Plan. The Share Options have a strike price of $21.82 and vest in three equal annual installments beginning on April 18, 2025, provided, however, that all vesting of Share Options granted to a director shall cease if that director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit for Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F6 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent a single grant to Felix J. Baker of 12,000 RSUs on Table I and 24,000 Share Options on Table II. These grants, totaling 12,000 RSUs and 24,000 Share Options for Felix J. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F7 · ownership.nature: Pursuant to agreements between Felix J. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs.

F8 · ownership.nature: ADS each represent 1 Ordinary Share.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Includes 24,000 Share Options granted by the Issuer to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the 2020 Plan. The Share Options have a strike price of $21.82 and vest in three equal annual installments beginning on April 18, 2025, provided, however, that all vesting of Share Options granted to a director shall cease if that director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

SEC source: 0000950170-24-046415 · ownership.xml · derivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 24,000

Underlying: American Depositary Shares · 24,000 shares

Expires 2034-04-18

F10 · shares: Includes 24,000 Share Options granted by the Issuer to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the 2020 Plan. The Share Options have a strike price of $21.82 and vest in three equal annual installments beginning on April 18, 2025, provided, however, that all vesting of Share Options granted to a director shall cease if that director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

F10 · derivative.exercise_date: Includes 24,000 Share Options granted by the Issuer to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the 2020 Plan. The Share Options have a strike price of $21.82 and vest in three equal annual installments beginning on April 18, 2025, provided, however, that all vesting of Share Options granted to a director shall cease if that director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit for Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F6 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent a single grant to Felix J. Baker of 12,000 RSUs on Table I and 24,000 Share Options on Table II. These grants, totaling 12,000 RSUs and 24,000 Share Options for Felix J. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F7 · ownership.nature: Pursuant to agreements between Felix J. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs.

F8 · ownership.nature: ADS each represent 1 Ordinary Share.

F10 · ownership.nature: Includes 24,000 Share Options granted by the Issuer to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the 2020 Plan. The Share Options have a strike price of $21.82 and vest in three equal annual installments beginning on April 18, 2025, provided, however, that all vesting of Share Options granted to a director shall cease if that director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

SEC source: 0000950170-24-046415 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 6,449,320

F1 · shares: Includes 12,000 restricted stock units (each an "RSU") payable solely in American Depositary Shares ("ADS") of Bicycle Therapeutics plc (the "Issuer") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") on April 18, 2024, pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). Each RSU represents a contingent right to recieve one Ordinary Share.

F1 · ownership.nature: Includes 12,000 restricted stock units (each an "RSU") payable solely in American Depositary Shares ("ADS") of Bicycle Therapeutics plc (the "Issuer") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") on April 18, 2024, pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). Each RSU represents a contingent right to recieve one Ordinary Share.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit for Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F6 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent a single grant to Felix J. Baker of 12,000 RSUs on Table I and 24,000 Share Options on Table II. These grants, totaling 12,000 RSUs and 24,000 Share Options for Felix J. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F7 · ownership.nature: Pursuant to agreements between Felix J. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs.

F8 · ownership.nature: ADS each represent 1 Ordinary Share.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-046415 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 591,856

F1 · shares: Includes 12,000 restricted stock units (each an "RSU") payable solely in American Depositary Shares ("ADS") of Bicycle Therapeutics plc (the "Issuer") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") on April 18, 2024, pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). Each RSU represents a contingent right to recieve one Ordinary Share.

F1 · ownership.nature: Includes 12,000 restricted stock units (each an "RSU") payable solely in American Depositary Shares ("ADS") of Bicycle Therapeutics plc (the "Issuer") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") on April 18, 2024, pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). Each RSU represents a contingent right to recieve one Ordinary Share.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit for Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F6 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent a single grant to Felix J. Baker of 12,000 RSUs on Table I and 24,000 Share Options on Table II. These grants, totaling 12,000 RSUs and 24,000 Share Options for Felix J. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F7 · ownership.nature: Pursuant to agreements between Felix J. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs.

F8 · ownership.nature: ADS each represent 1 Ordinary Share.

SEC source: 0001415889-24-010760 · form4-04122024_040405.xml · nonDerivative · entry 1

Hannay Michael Charles Ferguson · CIK 0002015378 · CHIEF PROD & SUPPLY CHAIN OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,891

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.48 to $22.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-010414 · form4-04052024_040430.xml · nonDerivative · entry 1

Keen Nicholas · CIK 0001776881 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,803

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-010418 · form4-04052024_040440.xml · nonDerivative · entry 1

Lee Kevin · CIK 0001776938 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 387,270

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-010417 · form4-04052024_040436.xml · nonDerivative · entry 1

Skynner Michael · CIK 0001776582 · CHIEF TECHNOLOGY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,884

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-010416 · form4-04052024_040434.xml · nonDerivative · entry 1

Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,241

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-010415 · form4-04052024_040432.xml · nonDerivative · entry 1

Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,761

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-010413 · form4-04052024_040425.xml · nonDerivative · entry 1

Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,223

F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-008888 · form4-03212024_110306.xml · derivative · entry 1

Hannay Michael Charles Ferguson · CIK 0002015378 · CHIEF PROD & SUPPLY CHAIN OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,000

Underlying: Ordinary Shares · 58,000 shares

Expires 2034-03-19

F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on March 19, 2025 and the remaining shares in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-004638 · form4-02212024_090213.xml · derivative · entry 2

Sands Stephen H. · CIK 0001913319 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Ordinary Shares · 24,000 shares

Expires 2034-02-20

F3 · derivative.exercise_date: This option shall vest in three equal annual installments on February 20, 2025, February 20, 2026 and February 20, 2027.

SEC source: 0001415889-24-004638 · form4-02212024_090213.xml · nonDerivative · entry 1

Sands Stephen H. · CIK 0001913319 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

F1 · kind: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in three equal annual installments on February 20, 2025, February 20, 2026 and February 20, 2027.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

SEC source: 0001415889-24-003009 · form4-02082024_090249.xml · derivative · entry 2

Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,570

Underlying: Ordinary Shares · 41,570 shares

Expires 2034-02-06

F3 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-003009 · form4-02082024_090249.xml · nonDerivative · entry 1

Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

F1 · kind: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

SEC source: 0001209191-24-000888 · doc4.xml · nonDerivative · entry 2

Keen Nicholas · CIK 0001776881 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,593

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-24-000875 · doc4.xml · nonDerivative · entry 2

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,428

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-24-000890 · doc4.xml · nonDerivative · entry 2

Thompson Travis Alvin · CIK 0001983944 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,375

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-24-000879 · doc4.xml · nonDerivative · entry 2

Crockett Nigel · CIK 0001788580 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,716

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-24-000877 · doc4.xml · nonDerivative · entry 2

Milnes Alistair · CIK 0001901321 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,196

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-24-000876 · doc4.xml · nonDerivative · entry 2

Skynner Michael · CIK 0001776582 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,839

F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $18.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-24-000886 · doc4.xml · derivative · entry 2

Bourque Janice · CIK 0001783330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Ordinary Shares · 12,000 shares

Expires 2034-01-02

F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024.

SEC source: 0001209191-24-000886 · doc4.xml · nonDerivative · entry 1

Bourque Janice · CIK 0001783330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,750

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

SEC source: 0001209191-24-000888 · doc4.xml · derivative · entry 4

Keen Nicholas · CIK 0001776881 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,000

Underlying: Ordinary Shares · 56,000 shares

Expires 2034-01-02

F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter.

SEC source: 0001209191-24-000888 · doc4.xml · nonDerivative · entry 1

Keen Nicholas · CIK 0001776881 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,233

F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

SEC source: 0001209191-24-000875 · doc4.xml · derivative · entry 3

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Ordinary Shares · 155,000 shares

Expires 2034-01-02

F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter.

SEC source: 0001209191-24-000875 · doc4.xml · nonDerivative · entry 1

Lee Kevin · CIK 0001776938 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 399,131

F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

SEC source: 0001209191-24-000885 · doc4.xml · derivative · entry 2

Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Ordinary Shares · 12,000 shares

Expires 2034-01-02

F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024.

SEC source: 0001209191-24-000885 · doc4.xml · nonDerivative · entry 1

Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,750

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.

SEC source: 0001209191-24-000883 · doc4.xml · derivative · entry 2

Jordan Veronica GH · CIK 0001381123 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Ordinary Shares · 12,000 shares

Expires 2034-01-02

F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024.

SEC source: 0001209191-24-000883 · doc4.xml · nonDerivative · entry 1

Jordan Veronica GH · CIK 0001381123 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,750

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024.

F2 · price: Each RSU represents a contingent right to receive one ordinary share.